Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shweta Joshi

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Parasitology International|May 24, 2008
Molecular cloning and characterization of Brugia malayi hexokinaseAlok Ranjan Singh, Shweta Joshi, Rahul Arya, et al.
Thrombosis and Haemostasis|May 31, 2018
Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient MiceEsther J Cooke, Jenny Y Zhou, Tine Wyseure, et al.
Iscience|September 24, 2021
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphomaDhananjaya Pal, Kendra R Vann, Shweta Joshi, et al.
Plos One|August 18, 2017
Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotypeShweta Joshi, Alok R Singh, Simon S Wong, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2017
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasisForest H Andrews, Alok R Singh, Shweta Joshi, et al.
Frontiers in Immunology|June 23, 2023
Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastomaDeepak Rohila, In Hwan Park, Timothy V Pham, et al.
Molecular Cancer Therapeutics|August 7, 2016
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular CarcinomaAlok R Singh, Shweta Joshi, Adam M Burgoyne, et al.
Journal of Pediatric Hematology/Oncology|December 7, 2013
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumorsLisa L R Hartman, John R Crawford, Milan T Makale, et al.
Molecular Cancer Therapeutics|April 26, 2019
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerShweta Joshi, Alok R Singh, Kevin X Liu, et al.
Cancer Research|June 12, 2023
Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal AdenocarcinomaDeepak Rohila, In Hwan Park, Timothy V Pham, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Parasitology International|May 24, 2008
Molecular cloning and characterization of Brugia malayi hexokinaseAlok Ranjan Singh, Shweta Joshi, Rahul Arya, et al.
Thrombosis and Haemostasis|May 31, 2018
Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient MiceEsther J Cooke, Jenny Y Zhou, Tine Wyseure, et al.
Iscience|September 24, 2021
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphomaDhananjaya Pal, Kendra R Vann, Shweta Joshi, et al.
Plos One|August 18, 2017
Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotypeShweta Joshi, Alok R Singh, Simon S Wong, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2017
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasisForest H Andrews, Alok R Singh, Shweta Joshi, et al.
Frontiers in Immunology|June 23, 2023
Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastomaDeepak Rohila, In Hwan Park, Timothy V Pham, et al.
Molecular Cancer Therapeutics|August 7, 2016
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular CarcinomaAlok R Singh, Shweta Joshi, Adam M Burgoyne, et al.
Journal of Pediatric Hematology/Oncology|December 7, 2013
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumorsLisa L R Hartman, John R Crawford, Milan T Makale, et al.
Molecular Cancer Therapeutics|April 26, 2019
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerShweta Joshi, Alok R Singh, Kevin X Liu, et al.
Cancer Research|June 12, 2023
Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal AdenocarcinomaDeepak Rohila, In Hwan Park, Timothy V Pham, et al.
Pageof 5